Posts

Showing posts from March, 2023

From Surgical Robots to Care Robots: The Promise of Robotics in Healthcare

Image
  Introduction of Robots The introduction of robots in healthcare has revolutionized the way surgeries are conducted, and has significantly improved patient outcomes. Robotics in surgery refers to the use of robots to perform surgical procedures. These robots are designed to be precise and accurate, which allows surgeons to perform complex surgeries with ease. Robots in Healthcare Robots in healthcare are being used to assist surgeons in performing surgeries, deliver medication to patients, and even provide physical therapy. These robots have proven to be incredibly useful in improving patient outcomes, reducing the risk of complications, and decreasing the length of hospital stays. Types of Robots in Healthcare There are several types of robots being used in healthcare. Some of the most common include surgical robots, exoskeleton robots, care robots, service robots , and autonomous mobile robots. Each type of robot is designed to perform specific tasks and improve patient outcomes

The Future of Polycythemia Vera Treatment: Examining Besremi, Jakafi, and Rusfertide

Image
  Polycythemia Vera Treatment Landscape Jakafi (Ruxolitinib) , developed by Incyte, is an FDA-approved drug for the treatment of Polycythemia Vera . Jakafi is a JAK1/JAK2 inhibitor that works by reducing the overactive signaling of JAK1 and JAK2, which are associated with the symptoms of Polycythemia Vera . Jakafi’s patent expiration date is in 2027, but several companies have filed for generics. However, there might be a delay in the entry of generics due to legal disputes. PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches Besremi (Ropeginterferon alfa-2b) is a new entrant in the Polycythemia Vera market , developed by PharmaEssentia. It is a subcutaneous injection and has a different mode of action than Jakafi. Besremi is an interferon alpha-2b derivative that regulates the immune system and bone marrow, which can help control the overproduction of blood cells in Polycythemia Vera . Besremi was approved in the EU in 2020 and received FDA ap